{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:41:29Z","timestamp":1792024889242,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alphaviruses, such as Ross River (RRV) and chikungunya virus (CHIKV), cause significant global morbidity, with outbreaks of crippling joint inflammation and pain, leaving patients incapacitated for months to years. With no available vaccine or specific therapeutic for any alphaviral disease, and a growing economic and public health burden, there is a serious need for the development of specific therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study evaluated the safety and efficacy of pentosan polysulfate sodium (PPS) in subjects with RRV-induced arthralgia in a double-blind, placebo-controlled trial. Twenty subjects were randomized 2:1 to subcutaneous PPS (2\u2009mg\/kg) or placebo (sodium chloride 0.9%) twice weekly for 6\u00a0weeks. Safety evaluation included physical examination, concomitant medications, and laboratory findings. Efficacy assessments included change from baseline in joint function (hand grip strength and RAPID3) and quality of life (SF-36) at Days 15, 29, 39 and 81 after treatment initiation. Inflammatory and cartilage degradation biomarkers were exploratory endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PPS was well tolerated, with a similar proportion of subjects reporting at least one treatment-emergent adverse event (TEAE) in the treatment and placebo groups. Injection site reactions were the most common TEAE and occurred more frequently in the PPS group. Dominant hand grip strength and SF-36 scores improved with PPS at all time points assessed, with hand grip strength improvement of 6.99\u2009kg (<jats:italic>p<\/jats:italic>\u2009=\u20090.0189) higher than placebo at Day 15. PPS showed significant improvements versus placebo in adjusted mean relative change from baseline for RAPID3 Pain (<jats:italic>p<\/jats:italic>\u2009=\u20090.0197) and Total (<jats:italic>p<\/jats:italic>\u2009=\u20090.0101) scores at Day 15. At the conclusion of the study overall joint symptoms, assessed by RAPID3, showed near remission in 61.5% of PPS subjects versus 14.3% of placebo subjects. Additionally, PPS treatment improved COMP, CTX-II, CCL1, CXCL12, CXCL16 and CCL17 biomarker levels versus placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, the improvements in strength and joint symptoms warrant further evaluation of PPS as a specific treatment for RRV-induced and other forms of arthritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>This trial is registered at the Australian New Zealand Clinical Trials Registry #<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=372925&amp;isReview=true\">ACTRN12617000893303<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12891-021-04123-w","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T13:03:31Z","timestamp":1615554211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study"],"prefix":"10.1186","volume":"22","author":[{"given":"Ravi","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Duiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny A.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Skerrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G. D.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Siddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat","family":"Rifat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H. K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Georgius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara J.","family":"Hererro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"4123_CR1","first-page":"586","volume":"38","author":"B Barber","year":"2009","unstructured":"Barber B, Denholm JT, Spelman D. Ross River virus. Aust Fam Physician. 2009;38:586\u20139.","journal-title":"Aust Fam Physician"},{"key":"4123_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/1529-0131(200002)43:2<365::AID-ANR16>3.0.CO;2-E","volume":"43","author":"M Soden","year":"2000","unstructured":"Soden M, Vasudevan H, Roberts B, Coelen R, Hamlin G, Vasudevan S, La Brooy J. Detection of viral ribonucleic acid and histological analysis of inflamed synovium in Ross River virus infection. Arthritis Rheum. 2000;43:365\u20139.","journal-title":"Arthritis Rheum"},{"key":"4123_CR3","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.1073\/pnas.1101089108","volume":"108","author":"LJ Herrero","year":"2011","unstructured":"Herrero LJ, Nelson M, Srikiatkhachorn A, Gu R, Anantapreecha S, Fingerle-Rowson G, et al. Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis. Proc Natl Acad Sci. 2011;108:12048\u201353.","journal-title":"Proc Natl Acad Sci"},{"key":"4123_CR4","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1073\/pnas.1318859111","volume":"111","author":"W Chen","year":"2014","unstructured":"Chen W, Foo SS, Rulli NE, Taylor A, Sheng KC, Herrero LJ, et al. Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc Natl Acad Sci. 2014;111:6040\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"4123_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1128\/CMR.14.4.909-932.2001","volume":"14","author":"D Harley","year":"2001","unstructured":"Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev. 2001;14:909\u201332.","journal-title":"Clin Microbiol Rev"},{"key":"4123_CR6","unstructured":"Australian Government Department of Health. National Notifiable Diseases Surveillance System. Available from: http:\/\/www9.health.gov.au\/cda\/source\/rpt_3.cfm. Accessed 4 September 2020."},{"key":"4123_CR7","unstructured":"Australian Department of Health. Ross River virus infection case definition. Available from: http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cda-surveil-nndss-casedefs-cd_rrv.htm. Accessed 4 September 2020."},{"key":"4123_CR8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0307-742X(21)00556-7","volume":"12","author":"JR Fraser","year":"1986","unstructured":"Fraser JR. Epidemic polyarthritis and Ross River virus disease. Clin Rheum Dis. 1986;12:369\u201388.","journal-title":"Clin Rheum Dis"},{"issue":"4","key":"4123_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3201\/eid2304.160466","volume":"23","author":"D Tappe","year":"2017","unstructured":"Tappe D, Perez-Giron JV, Gomez-Medina S, G\u00fcnther S, Mu\u00f1oz-Fontela C, Schmidt-Chanasit J. Increased proinflammatory cytokine levels in prolonged arthralgia in Ross River virus infection. Emerg Infect Dis. 2017;23(4):702\u20134.","journal-title":"Emerg Infect Dis"},{"key":"4123_CR10","unstructured":"Lidbury B, Mahalingam S. A role for chemokine activity in alphavirus pathogenesis: evidence from the analysis of polyarthritis and myalgia post-Ross River virus infection. Madame Curie Bioscience Database. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK6082\/. Accessed 20 August 2020."},{"key":"4123_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijid.2017.01.041","volume":"57","author":"C Lau","year":"2017","unstructured":"Lau C, Aubry M, Musso D, Teissier A, Paulous S, Despr\u00e8s P, et al. New evidence for endemic circulation of Ross River virus in the Pacific Islands and the potential for emergence. Int J Infect Dis. 2017;57:73\u20136.","journal-title":"Int J Infect Dis"},{"key":"4123_CR12","first-page":"29853","volume":"5","author":"OW Lawande","year":"2015","unstructured":"Lawande OW, Obanda V, Bucht G, Mosomtai G, Otieno V, Ahlm C. Global emergence of Alphaviruses that cause arthritis in humans. Infect Ecol Epidemiol. 2015;5:29853.","journal-title":"Infect Ecol Epidemiol"},{"key":"4123_CR13","volume-title":"Antimicrobe: Infectious Disease & Antimicrobial Agents","author":"P Griffin","year":"2017","unstructured":"Griffin P. Ross River virus. In: Antimicrobe: Infectious Disease & Antimicrobial Agents; 2017. http:\/\/www.antimicrobe.org\/v28.asp. Accessed 6 July 2020."},{"issue":"3","key":"4123_CR14","first-page":"24","volume":"41","author":"P Gorczyca","year":"2016","unstructured":"Gorczyca P, Manniello M, Pisano M, Avena-Woods C. NSAIDs: balancing the risks and benefits. US Pharm. 2016;41(3):24\u20136.","journal-title":"US Pharm"},{"key":"4123_CR15","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms20205023","volume":"20","author":"Y Bedoui","year":"2019","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J, Guiraud P, Giry C, Jafar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20:5023.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"4123_CR16","doi-asserted-by":"publisher","first-page":"8063","DOI":"10.1128\/JVI.00224-15","volume":"89","author":"LJ Herrero","year":"2015","unstructured":"Herrero LJ, Foo SS, Sheng KC, Chen W, Forwood MR, Bucala R, Mahalingam S. Pentosan Polysulfate: a novel glycosaminoglycan-like molecule for effective treatment of Alphavirus-induced cartilage destruction and inflammatory disease. J Virol. 2015;89(15):8063\u201376.","journal-title":"J Virol"},{"key":"4123_CR17","unstructured":"A pilot study to investigate the effects of pentosan polysulfate sodium in Ross River virus induced arthralgia. Australian New Zealand Clinical Trials Registry (#ACTRN12617000893303). Available at: https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=372925&isReview=true. Accessed 08 Sept 2020."},{"key":"4123_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1756-0500-4-127","volume":"4","author":"NM Massy-Westropp","year":"2011","unstructured":"Massy-Westropp NM, Gill T, Taylor AW, Bohannon RW, Hill CL. Hand grip strength: age and gender stratified normative data in a population-based study. BMC Res Notes. 2011;4:127.","journal-title":"BMC Res Notes"},{"key":"4123_CR19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3899\/jrheum.080182","volume":"35","author":"T Pincus","year":"2008","unstructured":"Pincus T. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35:2136\u201347.","journal-title":"J Rheumatol"},{"key":"4123_CR20","doi-asserted-by":"crossref","unstructured":"Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks G, Loge JH, et al, on behalf of the European palliative care research collaborative. Studies comparing numeric rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manag. 2011;41:1073\u201393.","DOI":"10.1016\/j.jpainsymman.2010.08.016"},{"key":"4123_CR21","unstructured":"Optum SF-36 v2 Health survey. Available from: https:\/\/campaign.optum.com\/optum-outcomes\/what-we-do\/health-surveys.html?gclid=CILX2u2bwdICFQ2BvQodPPoJog. Accessed 24 June 2020."},{"issue":"1","key":"4123_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1589\/jpts.31.75","volume":"31","author":"RW Bohannon","year":"2019","unstructured":"Bohannon RW. Minimal clinically important difference for grip strength: a systematic review. J Phys Ther Sci. 2019;31(1):75\u20138.","journal-title":"J Phys Ther Sci"},{"issue":"1","key":"4123_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.180153","volume":"46","author":"MM Ward","year":"2019","unstructured":"Ward MM, Castrejon I, Bergman MJ, Alba MI, Guthrie LC, Pincus T. Minimal clinically important improvement of routine assessment of patient index data 3 in rheumatoid arthritis. J Rheumatol. 2019;46(1):27\u201330.","journal-title":"J Rheumatol"},{"key":"4123_CR24","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1002\/art.34631","volume":"64","author":"HI Nakaya","year":"2012","unstructured":"Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A. Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum. 2012;64:3553\u201363.","journal-title":"Arthritis Rheum"},{"key":"4123_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.curtheres.2005.12.012","volume":"66","author":"P Ghosh","year":"2005","unstructured":"Ghosh P, Edelman J, March L, Smith M. Effects of pentosan polysulfate in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled pilot study. Curr Ther Res. 2005;66:552\u201371.","journal-title":"Curr Ther Res"},{"key":"4123_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6904-10-7","volume":"10","author":"K Kumagai","year":"2010","unstructured":"Kumagai K, Shirabe S, Miyata N, et al. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis - an open clinical trial. BMC Clin Pharmacol. 2010;10:1\u201324.","journal-title":"BMC Clin Pharmacol"},{"issue":"7","key":"4123_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/jor.22324","volume":"31","author":"P Verma","year":"2013","unstructured":"Verma P, Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. J Orthop Res. 2013;31(7):999\u20131006.","journal-title":"J Orthop Res"},{"key":"4123_CR28","doi-asserted-by":"crossref","unstructured":"Charni-Ben Tabassi N, Desmarais S, Bay-Jensen AC, Delaiss\u00e9 JM, Percival MD, Garnero P. The type II collagen fragments helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthr Cartil. 2008;16(10):1183\u201391.","DOI":"10.1016\/j.joca.2008.02.008"},{"key":"4123_CR29","doi-asserted-by":"crossref","unstructured":"Sironi M, Martinez FO, D\u2019Ambrosio D, Gattorno M, Polentarutti N, Locati M, et al. Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, type 2). J Leukoc Biol. 2006;80(2):342\u20139.","DOI":"10.1189\/jlb.1005586"},{"issue":"4","key":"4123_CR30","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.4049\/jimmunol.170.4.2147","volume":"170","author":"JL Pablos","year":"2003","unstructured":"Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003;170(4):2147\u201352.","journal-title":"J Immunol"},{"issue":"1","key":"4123_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13075-018-1560-9","volume":"20","author":"MC Lee","year":"2018","unstructured":"Lee MC, Saleh R, Achuthan A, Fleetwood AJ, F\u00f6rster I, Hamilton JA, et al. CCL17 blockade as a therapy for osteoarthritis pain and disease. Arthritis Res Ther. 2018;20(1):62.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"4123_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bone.2013.07.023","volume":"57","author":"K Ota","year":"2013","unstructured":"Ota K, Quint P, Weivoda MM, Ruan M, Pederson L, Westendorf JJ, et al. Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors. Bone. 2013;57(1):68\u201375.","journal-title":"Bone."},{"key":"4123_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1292\/jvms.11-0511","volume":"74","author":"T Sunaga","year":"2012","unstructured":"Sunaga T, Oh N, Hosoya K, Takagi S, Okumura M. Inhibitory effects of pentosan polysulphate sodium on MAP-kinase pathway and NF-kB translocation. J Vet Med Sci. 2012;74:707\u201311.","journal-title":"J Vet Med Sci"},{"key":"4123_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BJ20112159","volume":"443","author":"L Troeberg","year":"2012","unstructured":"Troeberg L, Mulloy B, Ghosh P, Lee MH, Murphy G, Nagase H. Pentosan Polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex. Biochem J. 2012;443:307\u201315.","journal-title":"Biochem J"},{"issue":"9","key":"4123_CR35","doi-asserted-by":"publisher","first-page":"e0222602","DOI":"10.1371\/journal.pone.0222602","volume":"14","author":"CJ Stapledon","year":"2019","unstructured":"Stapledon CJ, Tsangari H, Solomon LB, Campbell DG, Hurtado P, Krishnan R, Atkins GJ. Human osteocyte expression of nerve growth factor: the effect of pentosan polysulphate sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS. 2019;14(9):e0222602.","journal-title":"PLoS."},{"key":"4123_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.rvsc.2018.11.028","volume":"122","author":"HMS Wijekoon","year":"2019","unstructured":"Wijekoon HMS, Kim S, Bwalya EC, Fang J, Aoshima K, Hosoya K, Okumura M. Anti-arthritic effect of pentosan polysulfate in rats with collagen-induced arthritis. Res Vet Sci. 2019;122:179\u201385.","journal-title":"Res Vet Sci"},{"key":"4123_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12891-017-1754-3","volume":"18","author":"MJ Sampson","year":"2017","unstructured":"Sampson MJ, Kabbani M, Krishnan R, Nganga M, Theodoulou A, Krishnan J. Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral bone marrow edema lesion and joint effusion in an osteoarthritic patient following pentosan polysulphate sodium treatment: a case report. BMC Musculoskelet Disord. 2017;18:396.","journal-title":"BMC Musculoskelet Disord"},{"key":"4123_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13075-019-1951-6","volume":"21","author":"Z Huang","year":"2019","unstructured":"Huang Z, Chen J, Hu QS, Huang Q, Ma J, Pei FX, et al. Meta-analysis of pain and function placebo responses in pharmacological osteoarthritis trials. Arthritis Res Ther. 2019;21:173.","journal-title":"Arthritis Res Ther"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04123-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-021-04123-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-021-04123-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T08:45:27Z","timestamp":1671612327000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-021-04123-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4123"],"URL":"https:\/\/doi.org\/10.1186\/s12891-021-04123-w","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Bellberry Human Research Ethics Committee (HREC), Adelaide, Australia and conducted in accordance with the principles of the Declaration of Helsinki, the National Health & Medical Research Council National Statement on Ethical Conduct in Research Involving Humans, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Integrated Addendum To ICH E6(R1): Guideline For Good Clinical Practice E6(R2). It is registered at the Australian New Zealand Clinical Trials Registry #ACTRN12617000893303. All subjects provided informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Donna Skerrett, Ravi Krishnan, and Melanie Duiker are employees of Paradigm Biopharmaceuticals Ltd.Lara J Hererro is the recipient of the Australian National Health and Medical Research Council Career Development Award (ID: 105760).Penny A Rudd is the recipient of an Advanced Queensland Fellowship.James GD Pollard, Carolyn Siddel, Rifat Rifat and Jennifer HK Ng have no conflicts of interest.Peter Georgius has been a paid consultant for Abbott, Boston Scientific, and Canopy Growth.Paul Griffin has no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}